CellaVision AB And Sysmex Corporation Enhance Partnership By Signing A Global Distribution Agreement
Published: Mar 18, 2010
LUND, SWEDEN--(Marketwire - March 18, 2010) -
CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, extends and broadens cooperation with Sysmex by entering a global distribution agreement. The agreement gives Sysmex a non-exclusive right to sell CellaVision's products in hematology laboratories worldwide.
"We extend our successful collaboration with Sysmex and enhance the agreement to comprise more markets, including Japan, the country of origin for Sysmex Corporation", says Yvonne Martensson, CEO of CellaVision. "Sysmex has the global leadership position within hematology, and we are extremely pleased that they continue to promote and sell our analyzers to their customers, providing us with a very strong sales channel and the ability to carry on our market penetration. Sysmex is the perfect partner and strategic match in our commitment to strengthen our position as world leader within digital morphology analysis to hematology laboratories."
Sysmex and CellaVision have been developing their partnership since 2001, when they partnered in the European market. Sysmex Corporation, based in Kobe, Japan, is a world leader in clinical laboratory testing for blood, urine and other specimen. By adding CellaVision's products to their range, Sysmex can offer their customers a complete line of automated laboratory instruments, that is to say instruments for every step of the analytical process, from sample preparation to cell counters and final assessment in CellaVision's analyzers.
Starting April 1, 2010, the non-exclusive agreement comprises all international markets but Canada.
CellaVision continues to sell direct through its own sales organizations in the Nordic countries, the US, Canada and Japan. In 2009, Europe accounted for 41% of sales, North America for 55% and the rest of the world for 4%.
For more information, please contact: Yvonne Martensson, CEO, CellaVision AB Phone: + 708 33 77 82. E-mail: email@example.com
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 42 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a real difference in the health of people worldwide. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, China and Asia Pacific and employs more than 4,500 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange. For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.com.
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in the US, Canada and Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.